Maintenance Strategies Post-Autologous Stem Cell Transplantation for Newly Diagnosed Multiple Myeloma
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- Umfang
-
1 Online-Ressource.
- Sprache
-
Englisch
- Erschienen in
-
Maintenance Strategies Post-Autologous Stem Cell Transplantation for Newly Diagnosed Multiple Myeloma ; volume:2 ; number:2 ; day:20 ; month:5 ; year:2020 ; pages:59-68 ; date:6.2020
Clinical hematology international ; 2, Heft 2 (20.5.2020), 59-68, 6.2020
- Urheber
-
Bird, Sarah
Jackson, Graham
Pawlyn, Charlotte
- Beteiligte Personen und Organisationen
-
SpringerLink (Online service)
- DOI
-
10.2991/chi.d.200502.001
- URN
-
urn:nbn:de:101:1-2405140822589.225870716208
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
14.08.2025, 11:02 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Bird, Sarah
- Jackson, Graham
- Pawlyn, Charlotte
- SpringerLink (Online service)
Ähnliche Objekte (12)
Single versus tandem autologous stem cell transplantation in newly diagnosed multiple myeloma
RVD induction and autologous stem cell transplantation followed by lenalidomide maintenance in newly diagnosed multiple myeloma: a phase 2 study of the Finnish Myeloma Group
Newly diagnosed multiple myeloma patients with CD56 expression benefit more from autologous stem cell transplantation
Trends in Autologous Stem Cell Transplantation for Newly Diagnosed Multiple Myeloma: Lessons for Resource-Challenged Regions
Real-world results of autologous stem cell transplantation in newly diagnosed multiple myeloma: a report from the Canadian Myeloma Research Group database
Treatment benefit of upfront autologous stem cell transplantation for newly diagnosed multiple myeloma: a systematic review and meta-analysis
Ixazomib, lenalidomide, and dexamethasone in patients with newly diagnosed multiple myeloma: long-term follow-up including ixazomib maintenance
Autologous Stem Cell Collection after Daratumumab, Bortezomib, Thalidomide, and Dexamethasone versus Bortezomib, Cyclophosphamide, and Dexamethasone in Newly Diagnosed Multiple Myeloma
Impact of the time interval between end of induction and autologous hematopoietic transplantation in newly diagnosed patients with multiple myeloma
Muscle and fat composition in patients with newly diagnosed multiple myeloma
Maintenance therapy for newly diagnosed epithelial ovarian cancer– a review
European Myeloma Network recommendations on the evaluation and treatment of newly diagnosed patients with multiple myeloma
Single versus tandem autologous stem cell transplantation in newly diagnosed multiple myeloma
RVD induction and autologous stem cell transplantation followed by lenalidomide maintenance in newly diagnosed multiple myeloma: a phase 2 study of the Finnish Myeloma Group
Newly diagnosed multiple myeloma patients with CD56 expression benefit more from autologous stem cell transplantation
Trends in Autologous Stem Cell Transplantation for Newly Diagnosed Multiple Myeloma: Lessons for Resource-Challenged Regions
Real-world results of autologous stem cell transplantation in newly diagnosed multiple myeloma: a report from the Canadian Myeloma Research Group database
Treatment benefit of upfront autologous stem cell transplantation for newly diagnosed multiple myeloma: a systematic review and meta-analysis
Ixazomib, lenalidomide, and dexamethasone in patients with newly diagnosed multiple myeloma: long-term follow-up including ixazomib maintenance
Autologous Stem Cell Collection after Daratumumab, Bortezomib, Thalidomide, and Dexamethasone versus Bortezomib, Cyclophosphamide, and Dexamethasone in Newly Diagnosed Multiple Myeloma
Impact of the time interval between end of induction and autologous hematopoietic transplantation in newly diagnosed patients with multiple myeloma
Muscle and fat composition in patients with newly diagnosed multiple myeloma
Maintenance therapy for newly diagnosed epithelial ovarian cancer– a review
European Myeloma Network recommendations on the evaluation and treatment of newly diagnosed patients with multiple myeloma
Single versus tandem autologous stem cell transplantation in newly diagnosed multiple myeloma
RVD induction and autologous stem cell transplantation followed by lenalidomide maintenance in newly diagnosed multiple myeloma: a phase 2 study of the Finnish Myeloma Group
Newly diagnosed multiple myeloma patients with CD56 expression benefit more from autologous stem cell transplantation
Trends in Autologous Stem Cell Transplantation for Newly Diagnosed Multiple Myeloma: Lessons for Resource-Challenged Regions
Real-world results of autologous stem cell transplantation in newly diagnosed multiple myeloma: a report from the Canadian Myeloma Research Group database
Treatment benefit of upfront autologous stem cell transplantation for newly diagnosed multiple myeloma: a systematic review and meta-analysis
Ixazomib, lenalidomide, and dexamethasone in patients with newly diagnosed multiple myeloma: long-term follow-up including ixazomib maintenance
Autologous Stem Cell Collection after Daratumumab, Bortezomib, Thalidomide, and Dexamethasone versus Bortezomib, Cyclophosphamide, and Dexamethasone in Newly Diagnosed Multiple Myeloma
Impact of the time interval between end of induction and autologous hematopoietic transplantation in newly diagnosed patients with multiple myeloma
Muscle and fat composition in patients with newly diagnosed multiple myeloma
Maintenance therapy for newly diagnosed epithelial ovarian cancer– a review